Patents Assigned to Vernalis (R&D) Limited
-
Publication number: 20240025893Abstract: A compound represented by the general formula (1) or a salt thereof, which has a superior IRAK-4 inhibitory activity, and is useful as active ingredients of medicaments for prophylactic treatment and/or therapeutic treatment of diseases relating to IRAK-4 inhibition.Type: ApplicationFiled: September 30, 2020Publication date: January 25, 2024Applicants: Asahi Kasei Pharma Corporation, Vernalis (R&D) LimitedInventors: Koichiro ARAI, Kenichiro TAKABA, Masakazu ATOBE, Misato TAKASHIMA, Naomi AONO, Andrew John POTTER, Daniel Paul MADDOX
-
Publication number: 20230357271Abstract: A compound represented by the general formula (1) or a salt thereof, which has a superior IRAK-4 inhibitory activity, and is useful as active ingredients of medicaments for prophylactic treatment and/or therapeutic treatment of diseases relating to IRAK-4 inhibition.Type: ApplicationFiled: September 30, 2020Publication date: November 9, 2023Applicants: Asahi Kasei Pharma Corporation, Vernalis (R&D) LimitedInventors: Takahiko ITO, Misato TAKASHIMA, Masakazu ATOBE, Koichiro ARAI, Tomohisa TOYAMA, Yu YOSHII, Andrew John POTTER, Daniel Paul MADDOX, Stuart RAY, Nicolas FOLOPPE
-
Patent number: 11466019Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.Type: GrantFiled: November 3, 2020Date of Patent: October 11, 2022Assignee: Vernalis (R&D) LimitedInventors: Samantha Jane Bamford, Roger John Gillespie, Richard Simon Todd
-
Patent number: 11234987Abstract: Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: wherein R1, is a group of formula (IA): —Ar1-(Alk1)p-(Z)r-(Alk2)s-Q, wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1, Z is -0-, —S—, —(C?O)—, —(C?S)—, —SO.sub.Type: GrantFiled: July 31, 2019Date of Patent: February 1, 2022Assignees: Cancer Research Technology Limited, The Institute of Cancer Research, Vernalis (R&D) LimitedInventors: Martin James Drysdale, Brian William Dymock, Harry Finch, Paul Webb, Edward McDonald, Karen Elizabeth James, Kwai Ming Cheung, Thomas Peter Matthews
-
Publication number: 20210206762Abstract: The inventions relates to compounds of (I) and therapeutic uses thereof: (I) The terms Z, Y, and R1 are as defined in the claims.Type: ApplicationFiled: November 30, 2020Publication date: July 8, 2021Applicant: Vernalis (R&D) LimitedInventors: Stephen Stokes, Christopher John Graham, Stuart Christopher Ray, Emma Jayne Stefaniak
-
Patent number: 11028097Abstract: Compounds of formula (I) are A2B receptor antagonists: Wherein R1 is optionally substituted aryl or an optionally substituted 5- or 6-membered heteroaryl ring; R2 and R3 are independently selected from hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl-(C1-C6)-alkyl, aryl-(C1-C6)-alkyl optionally substituted in the ring part thereof, a 5- or 6-membered monocyclic heterocyclic group optionally linked via a C1-C6 alkylene chain and optionally substituted in the ring part thereof, benzimidazol-2-yl-methyl, pyrid-3-yl-carbonyl, or (1-methyl-piperidin-4-yl)-carbonyl-methyl; or R2 and R3 taken together with the nitrogen atom to which they are attached form an optionally substituted 5- or 6-membered ring; R4 is C1-C3 alkyl, C2-C3 alkenyl, —N(—R5)—R6, or optionally substituted heteroarylmethylamino; and R5 and R6 are independently selected from hydrogen or C1-C3 alkyl; or R5 and R6 taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 6-membered saturated rinType: GrantFiled: December 24, 2019Date of Patent: June 8, 2021Assignee: Vernalis (R&D) LimitedInventors: Allan Jordan, Simon Bedford, Klenke Burkhard, Ian Yule, Karine Poullennec
-
Publication number: 20210115054Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.Type: ApplicationFiled: November 3, 2020Publication date: April 22, 2021Applicant: Vernalis (R&D) LimitedInventors: Samantha Jane Bamford, Roger John Gillespie, Richard Simon Todd
-
Patent number: 10889582Abstract: The inventions relates to compounds of (I) and therapeutic uses thereof: (I) The terms Z, Y, and R1 are as defined in the claims.Type: GrantFiled: June 15, 2018Date of Patent: January 12, 2021Assignee: Vernalis (R&D) LimitedInventors: Stephen Stokes, Christopher John Graham, Stuart Christopher Ray, Emma Jayne Stefaniak
-
Patent number: 10875868Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are. disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.Type: GrantFiled: December 2, 2019Date of Patent: December 29, 2020Assignee: VERNALIS (R&D) LIMITEDInventors: Samantha Jane Bamford, Roger John Gillespie, Richard Simon Todd
-
Publication number: 20200172547Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are. disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.Type: ApplicationFiled: December 2, 2019Publication date: June 4, 2020Applicant: Vernalis (R&D) LimitedInventors: Samantha Jane Bamford, Roger John Gillespie, Richard Simon Todd
-
Patent number: 10538526Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.Type: GrantFiled: September 15, 2018Date of Patent: January 21, 2020Assignee: Vernalis (R&D) LimitedInventors: Samantha Jane Bamford, Roger John Gillespie, Richard Simon Todd
-
Patent number: 10413550Abstract: Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: wherein R1, is a group of formula (IA): —Ar1-(Alk1)p-(Z)r-(Alk2)s-Q, wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1, Z is —O—, —S—, —(C?O)—, —(C?S)—, —SO.sub.Type: GrantFiled: June 23, 2017Date of Patent: September 17, 2019Assignees: The Institute of Cancer Research, Cancer Research Technology Limited, Vernalis (R&D) LimitedInventors: Martin James Drysdale, Brian William Dymock, Harry Finch, Paul Webb, Edward McDonald, Karen Elizabeth James, Kwai Ming Cheung, Thomas Peter Matthews
-
Publication number: 20190031668Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.Type: ApplicationFiled: September 15, 2018Publication date: January 31, 2019Applicant: Vernalis (R&D) LimitedInventors: Samantha Jane Bamford, Roger John Gillespie, Richard Simon Todd
-
Patent number: 10106547Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.Type: GrantFiled: August 21, 2017Date of Patent: October 23, 2018Assignee: Vernalis (R&D) LimitedInventors: Samantha Jane Bamford, Roger John Gillespie, Richard Simon Todd
-
Patent number: 10000481Abstract: The inventions relates to compounds of (I) and therapeutic uses thereof: (I) The terms Z, Y, and R1 are as defined in the claims.Type: GrantFiled: January 30, 2013Date of Patent: June 19, 2018Assignee: Vernalis (R&D) LimitedInventors: Stephen Stokes, Christopher John Graham, Stuart Christopher Ray, Emma Jayne Stefaniak
-
Publication number: 20170342081Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.Type: ApplicationFiled: August 21, 2017Publication date: November 30, 2017Applicant: Vernalis (R&D) LimitedInventors: Samantha Jane Bamford, Roger John Gillespie, Richard Simon Todd
-
Patent number: 9765080Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are. disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.Type: GrantFiled: June 2, 2016Date of Patent: September 19, 2017Assignee: Vernalis (R&D) LimitedInventors: Samantha Jane Bamford, Roger John Gillespie, Richard Simon Todd
-
Publication number: 20170088552Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are. disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.Type: ApplicationFiled: June 2, 2016Publication date: March 30, 2017Applicant: Vernalis (R&D) LimitedInventors: Samantha Jane Bamford, Roger John Gillespie, Richard Simon Todd
-
Patent number: 9376443Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.Type: GrantFiled: February 10, 2015Date of Patent: June 28, 2016Assignee: VERNALIS (R&D) LIMITEDInventors: Samantha Jane Bamford, Roger John Gillespie, Richard Simon Todd
-
Publication number: 20150291602Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are. disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.Type: ApplicationFiled: February 10, 2015Publication date: October 15, 2015Applicant: Vernalis (R&D) LimitedInventors: Samantha Jane Bamford, Roger John Gillespie, Richard Simon Todd